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of a case with expression of cytotoxic
markers and response
to clarithromycin
CD30+ cutaneous lymphoproliferative disorders (CLPDs) are usually
characterized by a benign clinical course. The prognostic value of
cytotoxic markers in these lymphomas has not been evaluated in large
series. We describe a case of borderline CD30+ CLPD with cytotoxic
phenotype, presenting in a 22-year-old male patient as an ulcer on the
forearm. He reported having had similar ulcers on the buttock and
thigh that spontaneously regressed over the course of 1 year. The lesion
resolved with a single course of clarithromycin; a subsequent lesion, too,
responded to clarithromycin, and no recurrences or systemic
involvement have been documented in the 9-month follow-up.
A conservative approach in the management of CD30+ CLPD is
recommended. We believe that the anti-inflammatory and apoptotic
effects of clarithromycin on T cells may have hastened the remission
process.
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The spectrum of CD30+ cutaneous lymphopro-
liferative disorders (CLPDs) represents the second
most common type of cutaneous T-cell lymphomas
(CTCLs) after mycosis fungoides (MF), compris-
ing approximately 30% of all CTCLs. This group
includes lymphomatoid papulosis (LyP), cutaneous
anaplastic large-cell lymphoma (cALCL) and border-
line cases.1,2 Both LyP and cALCL share a low-grade
malignant behavior characterized by frequent spon-
taneous regression of skin lesions and, in general,
excellent prognosis.3 The term ‘borderline cases’
refers to those in which a clear distinction between
LyP and cALCL cannot be made based on clinico-
pathologic correlation.1–4
Case report
A 21-year-old white male patient in good general
health presented with an ulcer of 4 months’ duration
on his left forearm (Fig. 1). The lesion had started as
an enlarging violaceous nodule that spontaneously
ulcerated, leaving an asymptomatic, oval-shaped,
5-cm large ulcer, with undermined infiltrated bor-
ders. He had similar but smaller nodules on his right
upper eyebrow and on the back of his left thigh
(Fig. 2).
On skin examination, there were two large
atrophic scars on his left buttock and on his right
thigh, with hypopigmented and erythematoviola-
ceous areas, measuring 15 and 3 cm, respectively
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Fig. 1. Asymptomatic, oval-shaped, 5-cm exsudative deep ulcer on
the forearm, with undermined infiltrated borders.
Fig. 2. Violaceous nodule on the posterior aspect of the thigh.
(Fig. 3); according to the patient, these scars resulted
from ulcers, similar to the one observed on the
forearm, that had arose and healed spontaneously
during the preceding year. There was neither lym-
phadenopathy nor hepatosplenomegaly. His per-
sonal and family histories were unremarkable.
Routine laboratory analysis (including autoim-
mune markers and viral serologies), ultrasonography
of the abdomen and radiologic examination of the
chest were all normal. Mycologic and mycobacterial
cultures from the lesions were negative.
A skin biopsy showed dense lymphoid infiltrates
occupying the whole dermis, with epidermal hyper-
plasia and prominent edema of the papillary dermis
(Fig. 4). There were some intraepidermal lympho-
cytes, but prominent epidermotropism was lacking.
In some areas, there was infiltration of the muscles.
Cytomorphology showed predominance of medium-
large atypical cells admixed with small lymphocytes
and histiocytes (Fig. 5). Phenotypic analyses revealed
strong positivity for CD30 (Fig. 6A); tumor cells were
Fig. 3. Large atrophic scar on the left buttock that resulted from the
evolution of a previous noduloulcerative lesion.
also positive for the cytotoxic markers T-cell intra-
cellular antigen-1 (TIA-1) and granzyme B (GrB)
(Fig. 6B); they were positive for CD45RO and partly
positive for CD2,MUM-1 and beta-F1. Other mark-
ers (CD3, CD4, CD5, CD8, CD20, CD56) were
negative. In situ hybridization for Epstein-Barr virus
transcripts (EBER-1) was negative. The proliferation
rate was over 90%.
As there was some evidence of ulcer infection, a
course of clarithromycin (CAM) was started at the
initial observation. Within 5 days the ulcer of the
forearm completely regressed, leaving an erythema-
tous atrophic scar (Fig. 7); the papule and nodule
of the eyebrow and thigh resolved with no residual
lesions, too. After therapy, a single nodule developed
on the posterior aspect of the leg, ulcerated and did
not regress after treatment with topical antibiotics
and corticosteroids; it resolved after another course
of oral CAM.
The patient has been followed up closely with no
recurrence of the disease to date (9 months after first
observation). So far, full-body computerized tomog-
raphy scan, bone marrow biopsy and peripheral
T cells phenotype analysis excluded extracutaneous
involvement.
Discussion
Clinicopathologic features of CD30+ CLPDs can
pose difficult diagnostic challenges, and histologic
criteria alone are often insufficient to differentiate
clearly between LyP and cALCL, particularly
concerning type C LyP.5 Primary lesions in LyP
are typically multiple erythematous, dome-shaped
papules or small nodules at different stages of
development that spontaneously regress within
weeks. In contrast, cALCL presents with solitary
or localized nodules or tumors that often show
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Fig. 4. Dense infiltrates of atypical lymphocytes within the entire
dermis. Please note pseudoepitheliomatous epidermal hyperplasia
and papillary dermal edema.
ulceration, but lack the spontaneous resolution
observed in lesions of LyP.6 In unclear cases, the
clinical course over time is used as decisive criteria
for the definitive diagnosis and choice of treatment,
and some authors suggest an observation period of
4–8 weeks to determine the natural evolution of the
skin lesions.3
The recurrent, generalized, self-healing nature of
the eruption observed in our patient clearly suggests a
diagnosis of LyP. On the other hand, several lesions
were of very large size, even exceeding 15 cm in
diameter, and the ulcer on the forearm did not reveal
a tendency to regression. In addition, the diffuse
infiltrate of CD30+ large atypical lymphocytes with
nuclear atypia suggests a histopathologic diagnosis
of cALCL, or of type C LyP. In short, our
patient presented with features of both entities,
thus representing a ‘borderline’ case. Even close
monitoring of the lesions during follow-up did not
clearly clarify the exact classification. Owing to the
spontaneous resolution of previous tumors, and to
the presence of lesions at different sites of the body,
we believe that our patient may have had a very
A
B
Fig. 5. A) Sheets of atypical lymphocytes with infiltration of amuscle;
(B) anaplastic features of neoplastic cells.
unusual form of LyP with giant tumors that showed
only partial spontaneous regression.
The time interval between the resolution of the
lesions and the two courses of CAM suggests that
the macrolide may have hastened the regression
process. In vitro studies have clearly proven that
macrolide antibiotics inhibit the proliferation of
human lymphocytes stimulated with polyclonal
T-cell mitogens;7 CAM was also found to suppress
the production of proinflammatory cytokines via
inhibition of nuclear factor-kB (NF-kB) activation,
a mechanism similar to cyclosporine action.8 More
recent studies showed that macrolide antibiotics,
namely CAM, induce apoptosis of human peripheral
lymphocytes through the Fas/Fas-ligand pathway
and downregulation of Bcl-xL.9,10 These effects could
account for the striking response that occurred in
our case. Nonetheless, due to the favorable course
observed in this type of lymphoma and to the
tendency for spontaneous regression, we cannot
extrapolate these results, although the temporal
relation is quite suggestive. Interestingly, CAM has
been used in unresectable non-small-cell lung cancer





Fig. 6. Positivity of neoplastic cells for (A) CD30 and (B) the cytotoxic
marker TIA-1.
with advanced disease,11,12 and has shown efficacy
in Helicobacter pylori-negative cases of low-grade
malignancy MALTomas (lymphomas of mucosa-
associated lymphoid tissue) of the rectum,13 by
directly inducing apoptosis in lung carcinoma cells
and B-cell lymphoma cells, respectively.
Another striking feature of this case was the
cytotoxic phenotype of neoplastic cells, with loss
of most T-cell markers. Expression of cytotoxic
markers (TIA-1 and GrB) can be found in 70–90%
of noncutaneous CD30+ ALCL of T-cell or null-cell
phenotype,14 in addition to natural killer (NK)/T-
cell lymphomas. As far as cutaneous lymphomas are
concerned, some studies have shown that cALCL
and LyP frequently express cytotoxic proteins.15,16
The prognostic value of cytotoxic markers is well
established for noncutaneous CD30+ lymphomas,17
but no study has addressed this issue in cutaneous
CD30+ lymphoproliferative disorders. Vermeer
et al. and Massone et al. reported that cases of
MF expressing GrB/TIA-1 do not have a more
aggressive clinical behavior or a worse prognosis
compared with cases of MF that do not express these
cytotoxic molecules.18,19 An increase of expression
of cytotoxic molecules can be observed in tumor
Fig. 7. Scar left from the resolution of the initial ulcer on the forearm.
stage MF, in particular in tumors showing blastic
transformation.18
The correlation between clinical and histologic
manifestations of CD30+ CLPD is not always
straightforward, and particularly borderline cases
present considerable difficulties in diagnosis and
classification.20 Clinicians and pathologists need to
be aware of the characteristic features of these entities
to avoid misdiagnosis and inappropriate treatment.
We believe that response to CAM in our case may
warrant further studies on the anti-inflammatory and
apoptotic effects on T cells of this molecule.
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